Identification and Validation of an Anthracycline/Cyclophosphamide–Based Chemotherapy Response Assay in Breast CancerJude M. Mulligan, Richard D. Kennedy, Olaide Y. Raji et al.|JNCI Journal of the National Cancer Institute|2014Cited by 127
Association of a DNA damage response deficiency (DDRD) assay and prognosis in early-stage esophageal adenocarcinoma.Richard Turkington, Richard D. Kennedy, Laura A. Hill et al.|Journal of Clinical Oncology|2014Cited by 3
Identification and validation of an assay predictive of response and prognosis following anthracycline-based chemotherapy for early breast cancer.Jude M. Mulligan, Richard D. Kennedy, Laura A. Hill et al.|Journal of Clinical Oncology|2013Cited by 0